Gracey Craig sold $25K of OMDA

Gracey Craig (Chief Accounting Officer) sold 1,041 shares of Omada Health, Inc. (OMDA) at $24.00 on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gracey Craig
Published Jul 15, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The disclosure confirms an open-market sale of 1,041 shares at $24.00, totaling $24,984, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure and small size reduce fundamental impact.

03

What to watch

The article provides no context on total planned sales, remaining 10b5-1 schedule, or whether the officer sold for diversification or tax reasons.

Relevance 2/10Novelty 2/10Timing: Filed on 2026-07-15 after-hours, reflecting a 2026-07-13 sale.

Background

This is an SEC Form 4 insider transaction for Omada Health, Inc., reported by Chief Accounting Officer Gracey Craig.

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

Omada Health insider Gracey Craig sold 1,041 shares at $24.00 on 2026-07-13 under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and typically fades.

Evidence & confidence

The filing is a Form 4 insider sale, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed transaction size is small relative to company-level fundamentals.

Market effects

No clear read-across to the digital health or care-delivery sector from a single small 10b5-1 sale.

None.

None.

Counterpoint

Even 10b5-1 sales can coincide with internal expectations, so some traders may briefly re-rate sentiment if they view the sale as risk-reducing.

Key entities

  • Omada Health, Inc.

    US-listed company whose insider sale is disclosed on Form 4.

  • Gracey Craig

    Chief Accounting Officer who executed the reported open-market sale.

  • 10b5-1 plan

    Pre-arranged plan intended to reduce timing-based inference from insider trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.